Tradestie Institutional Equity Comparison Engine

TECX vs NBP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TECX Overall Edge

TECX Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Tectonic Therapeutic, Inc. Common Stock (TECX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while NBP counters with relative strength in Valuation. Fundamentally, TECX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus NBP at 2.7x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, TECX sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro) against NBP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner NBP
TECX N/M vs NBP 2.7x Fwd P/E
Growth & Margin Winner TECX
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner TECX
1Y +19.3% vs -81.0% ยท 52W Pos 18% vs 0%
Options & Structure Winner TECX
BREAKDOWN (6th %ile IV) vs UNCLASSIFIED (N/A IV)
TECX NASDAQ
Tectonic Therapeutic, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$20.98
-0.76% 1D
Market Cap $411.3M
1M Return +1.6%
1Y Return +19.34%
Forward P/E N/M
Unified AI Score
36.5 / 100 SELL
Tech 20.0 Fund 52.0 Flow 61.0 Mom 50.0
NBP US Equity
NBP
Institutional Equity
$0.79
-6.87% 1D
Market Cap $96.3M
1M Return -37.18%
1Y Return -81.02%
Forward P/E 2.7x
Unified AI Score
51.9 / 100 HOLD
Tech 60.0 Fund 50.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: TECX +19.34% NBP -81.02% Spread: +100.36 pp (TECX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
TECX TTM Op. Margin: 0.0% NBP TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TECX vs NBP. Trailing 12-month operating profitability (TECX 0.0% vs NBP 0.0%) and valuation multiples (TECX N/M vs NBP 2.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: TECX (4) vs NBP (3)
Institutional Metric TECX NBP Criterion Row Winner
Market Capitalization Scale $411.3M $96.3M Larger Scale TECX
Trailing P/E Ratio Valuation N/M 2.7x Lower Multiple NBP
Forward P/E Ratio Valuation N/M 2.7x Lower Multiple NBP
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -35.5% -59.1% Higher ROE TECX
52-Week Range Position Momentum 18% ($17โ€“$40) 0% ($1โ€“$5) Stronger Trend TECX
Beta / 30D Volatility Risk Regime 1.15ฮฒ ยท 55% Vol 1.64ฮฒ ยท 80% Vol Lower Realized Risk TECX
Unified Institutional Score Composite Signal 36.5 / 100 (SELL) 51.9 / 100 (HOLD) Higher Composite NBP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full TECX vs NBP Buy Guide
TECX BREAKDOWN
176d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live TECX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NBP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live NBP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither TECX nor NBP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.